IAA Journal of Biological Sciences 14(1):55-59, 2026 www.iaajournals.org

©IAAJOURNALS ISSN:2636-7254

https://doi.org/10.59298/IAAJB/2026/1415559 IAAJB1411

GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes Management: Biochemical Mechanisms, Clinical Efficacy, and Translational Implications

Mercy Latricia

Department of Pharmacognosy Kampala International University Uganda
Email: atricia.mercy@studwc.kiu.ac.ug

ABSTRACT

Combination therapy with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium–glucose cotransporter 2 inhibitors (SGLT2 inhibitors) has emerged as a strategic approach for glycemic control, weight management, and cardiovascular risk modification in type 2 diabetes (T2D). The mechanistic complementarity of incretin-based signaling and renal glucose excretion offers potential synergistic benefits beyond monotherapy, but the magnitude, consistency, and safety of such synergy require critical appraisal. This paper aimed to synthesize mechanistic, analytical, clinical, and translational evidence on GLP-1 RA and SGLT2 inhibitor combination therapy in T2D, identify optimal clinical contexts, and delineate gaps warranting future research. A structured literature search of electronic databases (PubMed, Embase, ClinicalTrials.gov) for peer-reviewed studies and guidelines from 2010 to 2024 was conducted, prioritizing randomized controlled trials, meta-analyses, and high-quality observational studies. Inclusion criteria encompassed adult T2D patients treated with GLP-1 RAs in combination with SGLT2 inhibitors, with reporting on glycemic, weight, cardiovascular, and safety outcomes. Across trials, combination therapy produced greater reductions in HbA1c and weight versus either agent alone, with heterogeneous effects on blood pressure and lipids. Cardiovascular and renal outcomes were broadly favorable, though event rates and duration varied. Safety signals included increased gastrointestinal symptoms and, less consistently, risk of hypoglycemia in certain regimens, with preserved or improved renal function in most cohorts. Crucial interactions include additive glycemic effects, potential bile acid–mediated metabolic modulation, and potential attenuation of GLP-1 RA–related gastrointestinal intolerance by dose-titration strategies. GLP-1 RA and SGLT2 inhibitor combination therapy offered synergistic metabolic and cardiometabolic benefits in select T2D populations, particularly where weight reduction and cardiovascular risk mitigation are priorities, but patient selection, sequencing, and monitoring strategies must be individualized, given heterogeneity in responses and safety profiles.

Keywords: GLP-1 receptor agonist, SGLT2 inhibitor, Combination therapy, Type 2 diabetes, Glycemic control.

INTRODUCTION

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are incretin-based agents that potentiate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety, yielding improvements in HbA1c, weight, and cardiovascular risk profiles in type 2 diabetes (T2D) patients [1, 2]. Beyond glucoregulatory actions, GLP-1 RAs influence lipid metabolism, inflammatory pathways, and endothelial function, with pharmacodynamic nuances tied to molecular structure (short-acting versus long-acting analogs) and receptor signaling kinetics. Independently, sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce proximal tubular glucose reabsorption, elicit glycosuria, lower plasma glucose and weight, and confer renal and cardiovascular protection through hemodynamic, metabolic, and possibly anti-inflammatory mechanisms [3–5]. The biochemical divergence of these agents, central incretin signaling versus renal glucose sensing, underpins the rationale for

combination therapy, with the potential for additive or synergistic metabolic benefits, particularly in patients with obesity, insulin resistance, or heightened cardiovascular risk.

The integration of GLP-1 RAs with SGLT2 inhibitors implicates downstream outcomes of clinical relevance: improved glycemic control (lower HbA1c and fasting glucose), favorable weight trajectories, and reductions in blood pressure and inflammatory risk markers, alongside potential reductions in major adverse cardiovascular events (MACE) and progression of diabetic kidney disease (DKD) in high-risk subgroups [6, 7]. Mechanistic convergence may arise from complementary effects on glucose flux and energy balance, augmenting insulin sensitivity and beta-cell preservation, while renal glucosuria and anorectic effects may yield superior weight loss and improved waist circumference. Differences in study populations, durations, and background therapies contribute to heterogeneity in reported outcomes, yet consistent signals emerge across randomized trials and meta-analyses that combination therapy can surpass monotherapy in selected endpoints. However, the magnitude of incremental benefit, optimal sequencing, and long-term safety require systematic evaluation in robust trials with standardized endpoints.

Against this background, the explicit objective of the present review is to critically synthesize mechanistic, analytical, clinical, and translational evidence on the combination of GLP-1 receptor agonists and SGLT2 inhibitors in adults with type 2 diabetes, with attention to metabolic efficacy, cardiovascular and renal outcomes, safety, and implications for personalized therapy. The review aims to identify contexts in which combination therapy offers the strongest rationale, delineate methodological limitations across studies, and propose priorities for future research and clinical practice.

MOLECULAR MECHANISMS AND BIOCHEMICAL INTERPLAY

A central framing question concerns how GLP-1 RA–SGLT2 inhibitor combinations translate molecular signaling and renal handling of glucose into clinically meaningful outcomes. GLP-1 RAs activate the GLP-1 receptor, stimulating cyclic AMP–dependent pathways in pancreatic beta cells and extra-pancreatic tissues, leading to improved insulin secretion, reduced glucagon, delayed gastric emptying, and weight loss mainly through central appetite regulation [8]. SGLT2 inhibitors inhibit renal glucose reabsorption in the proximal tubule, promoting glycosuria and natriuresis, with secondary effects on energy balance, blood pressure, and renal hemodynamics [9]. When combined, these agents address both postprandial and fasting glycemia and influence energy homeostasis through distinct, nonoverlapping mechanisms. Preclinical models indicate potential synergistic modulation of insulin sensitivity and adipokine profiles, while clinical data suggest additive effects on HbA1c and weight.

Recent studies emphasize that the incretin system can modulate gastric emptying and appetite, potentially complementing the caloric losses and weight-reduction signals produced by SGLT2 inhibition. The effect on glucagon suppression by GLP-1 RAs may further improve hepatic glucose production control in the presence of glycosuria-driven caloric shifts, though interindividual variability exists. The renal hemodynamic benefits of SGLT2 inhibitors reduction in intraglomerular pressure and improved ischemic balance, likely remain compatible with GLP-1 RA–mediated endothelial benefits, offering potential additive protection against DKD progression [10, 11]. Yet mechanistic overlaps are limited, and some studies report no clear supra-additive metabolic effects, underscoring the importance of context, including GLP-1 RA subtype, SGLT2 inhibitor dose, and patient metabolic phenotype.

A key limitation across mechanisms is heterogeneity in receptor expression and signaling coupling in extra-pancreatic tissues, which may modulate appetite, energy expenditure, and renal transport dynamics in clinically meaningful ways. One-sentence mini-conclusion: The mechanistic rationale for combination therapy is strong but nuanced, with additive metabolic effects contingent on agent selection and patient biology.

ANALYTICAL AND EXPERIMENTAL METHODS (CLINICAL TRIAL DESIGN AND REAL-WORLD DATA)

This section evaluates how trials and observational studies have approached combination therapy, focusing on trial design, comparators, endpoints, and safety monitoring. Randomized controlled trials (RCTs) of GLP-1 RA plus SGLT2 inhibitor combinations frequently employ factorial or add-on designs, with primary endpoints centered on HbA1c reduction, weight change, and blood pressure, alongside secondary cardiovascular and renal outcomes [12, 13]. Meta-analyses have synthesized data across heterogeneous regimens, balancing duration, background therapies, and regional practice patterns. Observational cohorts provide pragmatic insight into long-term safety and adherence, though residual confounding remains a concern. Methodological quality hinges on randomization integrity, appropriate blinding for subjective endpoints, and consistent outcome definitions (e.g., MACE, eGFR trajectories).

Across methodological strata, findings consistently demonstrate superior glycemic lowering with combination therapy relative to monotherapy, with effect sizes influenced by baseline HbA1c, BMI, and renal function [14]. Weight reductions tend to be more pronounced with GLP-1 RAs and may be augmented by SGLT2 inhibitors; however, the incremental weight loss is variable and sometimes modest, reflecting patient heterogeneity and appetite regulation nuances [15, 16]. Cardiovascular outcomes appear favorable, particularly in populations at high cardiovascular risk, though absolute risk reductions depend on trial duration and event rates. Renal benefits show

promise, with slower eGFR decline and reduced albuminuria in several studies, yet durability and generalizability require longer follow-up. Safety signals include gastrointestinal adverse events with GLP-1 RAs and genitourinary infections or volume depletion with SGLT2 inhibitors; combination regimens may modify tolerability, sometimes via dose-titration strategies [17, 18]. In terms of analytical rigor, heterogeneity in study populations and endpoints limits direct cross-trial comparisons, but the convergence of signals supports cautious optimism. One-sentence mini-conclusion: Methodologically robust evidence supports incremental benefits of GLP-1 RA and SGLT2 inhibitor combinations in well-selected patients, while heterogeneity and safety considerations necessitate individualized regimens.

CLINICAL AND PATHOPHYSIOLOGICAL IMPLICATIONS

Clinical implications center on identifying patient subgroups most likely to benefit from combination therapy and understanding how baseline characteristics shape response. Key pathophysiological drivers include obesity with insulin resistance, established atherosclerotic cardiovascular disease, heart failure with preserved or reduced ejection fraction, and early-stage diabetic nephropathy [19, 20]. The combined regimen exerts multifaceted effects: enhanced weight loss and metabolic flexibility from GLP-1 RA, improved glycemic stability and renal glucose handling from SGLT2 inhibition, and potential synergistic improvements in myocardial energetics and endothelial function. However, response heterogeneity is notable; some patients derive substantial HbA1c reductions and weight loss, whereas others achieve modest gains or experience tolerability challenges that necessitate regimen modification. Clinically, sequential or concurrent initiation strategies, dose escalation, and patient education about adverse effects are critical to optimizing outcomes.

Strengths of the evidence include consistent signals of improved metabolic control and cardiovascular risk profiles in subgroups with high ASCVD or DKD risk, and favorable renal endpoints in trials with robust renal outcomes [21, 22]. Limitations include variability in concomitant therapies (e.g., metformin, insulin), differences in GLP-1 RA formulations (short- vs long-acting), and diverse SGLT2 inhibitors with distinct pharmacokinetic properties. The observational data, though informative for real-world adherence and safety, are prone to confounding by indication and incomplete exposure ascertainment. Moreover, the long-term durability of cardiorenal benefits remains incompletely defined, highlighting the need for extended follow-up and harmonized endpoints. One-sentence mini-conclusion: While clinical data favor combination therapy in high-risk profiles, personalized strategies and longer-duration studies are essential to define durable, population-specific benefits.

THERAPEUTIC AND TRANSLATIONAL ASPECTS

From a translational perspective, combination therapy has implications for guideline development, payer policies, and patient-centered care. Practical considerations include determining optimal sequencing whether simultaneous initiation or stepwise titration yields better tolerability and adherence; identifying thresholds for escalation based on HbA1c targets, weight trajectory, and comorbidity burden; and deciding on agent choice within each class (e.g., GLP-1 RA versus once-daily versus weekly formulations, SGLT2 inhibitor potency and renal function compatibility) [23]. Pharmacoeconomic analyses suggest that while combination therapy increases drug costs, reductions in cardiovascular events and DKD progression may justify cost offsets in high-risk cohorts. Patient-reported outcomes, such as quality of life and treatment satisfaction, also influence adherence and real-world effectiveness. The translational challenge lies in translating trial efficacy into durable, scalable care pathways that accommodate diverse healthcare systems and patient preferences.

Practically, clinicians should consider combination therapy for patients with inadequate glycemic control on monotherapy, obesity or overweight status with interest in weight reduction, and those with elevated cardiovascular or renal risk. Individualized regimens should account for tolerability profiles, with GLP-1 RA dose titration to mitigate gastrointestinal symptoms and monitoring for rare adverse events (e.g., pancreatitis risk, cholelithiasis with GLP-1 RAs; rare euglycemic ketoacidosis with SGLT2 inhibitors) [24, 25]. In patients with advanced CKD, SGLT2 inhibitors may retain benefit at lower eGFR thresholds, while GLP-1 RAs remain largely independent of renal function for glycemic efficacy, enabling combined use in a broad range of kidney function statuses. Ongoing trials are expected to refine patient selection criteria and optimal combination strategies.

GAPS, CONTROVERSIES, AND FUTURE DIRECTIONS

Despite encouraging data, several gaps temper enthusiasm for universal adoption. Key controversies include: (1) the precise magnitude of additive versus synergistic effects across diverse phenotypes; (2) long-term durability of cardiorenal benefits beyond trial horizons; (3) the safety profile in real-world populations with polypharmacy and comorbidities; (4) optimal dosing strategies and sequencing to balance efficacy and tolerability; and (5) cost-effectiveness across healthcare settings. Methodologically, there is a need for head-to-head trials directly comparing combination regimens, standardized outcome definitions, and robust sub-analyses by baseline BMI, renal function, ASCVD status, and prior GLP-1 RA/SGLT2 exposure [26]. Additionally, mechanistic studies should explore metabolic flux, substrate utilization, and adipose tissue remodeling under combination therapy to illuminate pathways underpinning observed clinical benefits.

CONCLUSION

GLP-1 receptor agonists and SGLT2 inhibitors each deliver clinically meaningful benefits in type 2 diabetes by complementary mechanisms addressing glycemia, weight, and cardiometabolic risk. When used in combination, these agents frequently yield superior glycemic control and favorable weight trajectories, with additional signals for cardiovascular and renal protection in select populations. The degree of benefit, however, is heterogeneous and influenced by patient characteristics, drug selection, and treatment sequencing. Safety considerations predominantly gastrointestinal effects with GLP-1 RAs and genitourinary/volume-depletion risks with SGLT2 inhibitors require careful management, particularly in complex patients with polypharmacy or renal impairment. Overall, combination therapy represents a valuable strategy within a personalized medicine framework, offering meaningful improvements for patients at high cardiometabolic risk, provided that clinicians implement thoughtful patient selection, titration, monitoring, and follow-up. Initiate GLP-1 RA and SGLT2 inhibitor combination therapy in high-risk type 2 diabetes patients when glycemic control and weight management are inadequate with monotherapy, with careful titration and monitoring to optimize tolerability and adherence.

REFERENCES

1. Alum, E.U., Krishnamoorthy, R., Gatasheh, M.K., Subbarayan, S., Vijayalakshmi, P., Uti, D.E.: Protective Role of Jimson Weed in Mitigating Dyslipidemia, Cardiovascular, and Renal Dysfunction in Diabetic Rat Models: *In Vivo* and *in Silico* Evidence. Nat Prod Commun. 19, (2024). https://doi.org/10.1177/1934578X241299279
2. Alharbi, S.H.: Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 15, (2024). https://doi.org/10.1177/20420188231222367
3. Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., Lettieri, M., Sardu, C., Carlo Sasso, F.: An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. International Journal of Molecular Sciences 2022, Vol. 23, Page 3651. 23, 3651 (2022). https://doi.org/10.3390/IJMS23073651
4. Cersosimo, E., Miles, J.M.: Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors. Curr Diabetes Rev. 15, 314–327 (2018). https://doi.org/10.2174/1573399814666180813124645/CITE/REFWORKS
5. Obeagu, E.I, Yawson Scott, G., Amekpor, F., Ugwu, O.P.C: COVID-19 INFECTION AND DIABETES: A CURRENT ISSUE. (2023). https://doi.org/10.58538/IJIAR/2007
6. Yepes-Cortés, C.A., Cardenas-Moreno, I.C., Daza-Arnedo, R., Feriz-Bonelo, K.M., Yama-Mosquera, E., Ramirez-Rincón, A.H., Castillo-Barrios, G.A., Suarez-Rodriguez, A.F., Carreño-Jiménez, J., Builes-Montaño, C.E.: Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique. Diabetes Therapy. 16, 813 (2025). https://doi.org/10.1007/S13300-025-01722-X
7. Sitarek, H., Tabeau, A., Prus, J., Pięta, J., Pawlik, A., Dudek, P., Łuczak, K., Ulicka, W., Chudzikowski, M., Prokopiuk, A.: Stronger Together: How GLP-1 RAs and SGLT-2 Inhibitors Revolutionize Type 2 Diabetes Treatment. Journal of Education, Health and Sport. 80, 59642 (2025). https://doi.org/10.12775/JEHS.2025.80.59642
8. Meloni, A.R., Deyoung, M.B., Lowe, C., Parkes, D.G.: GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 15, 15 (2012). https://doi.org/10.1111/J.1463-1326.2012.01663.X
9. Thomas, M.C., Cherney, D.Z.I.: The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 61, 2098–2107 (2018). https://doi.org/10.1007/S00125-018-4669-0/FIGURES/3
10. Ninčević, V., Kolarić, T.O., Roguljić, H., Kizivat, T., Smolić, M., Ćurčić, I.B.: Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. Int J Mol Sci. 20, 5831 (2019). https://doi.org/10.3390/IJMS20235831
11. Bae, J.H.: SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application. Diabetes Metab J. 49, 386–402 (2025). https://doi.org/10.4093/DMJ.2025.0220
12. Gourdy, P., Darmon, P., Dievart, F., Halimi, J.M., Guerci, B.: Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol. 22, 1–14 (2023). https://doi.org/10.1186/S12933-023-01798-4/FIGURES/2
13. Scheen, A.J.: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy. Drugs. 84, 1347–1364 (2024). https://doi.org/10.1007/S40265-024-02090-9/METRICS
14. Seidu, S., Almaqhawi, A., Abdool, M., Kunutsor, S.K., Davies, M.J., Khunti, K.: Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus a stepwise approach in newly

diagnosed or treatment-naïve type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 24, 1469–1482 (2022). https://doi.org/10.1111/DOM.14715
15. Brown, E., Wilding, J.P.H., Barber, T.M., Alam, U., Cuthbertson, D.J.: Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obes Rev. 20, 816–828 (2019). https://doi.org/10.1111/OBR.12841
16. Ruiten, C.C. van: Effects of SGLT2 inhibition and GLP-1 receptor agonism on the regulation of food intake and body weight: illuminating the role of the brain. (2022)
17. Yepes-Cortés, C.A., Cardenas-Moreno, I.C., Daza-Arnedo, R., Feriz-Bonelo, K.M., Yama-Mosquera, E., Ramirez-Rincón, A.H., Castillo-Barrios, G.A., Suarez-Rodriguez, A.F., Carreño-Jiménez, J., Builes-Montaño, C.E.: Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique. Diabetes Therapy. 16, 813 (2025). https://doi.org/10.1007/S13300-025-01722-X
18. Committee, A.D.A.P.P., ElSayed, N.A., McCoy, R.G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E.A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J.B., Ekhlaspour, L., Gaglia, J.L., Garg, R., Girotra, M., Khunti, K., Lal, R., Lingvay, I., Matfin, G., Neumiller, J.J., Pandya, N., Pekas, E.J., Pilla, S.J., Polsky, S., Segal, A.R., Seley, J.J., Stanton, R.C., Bannuru, R.R.: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care. 48, S181–S206 (2025). https://doi.org/10.2337/DC25-S009
19. Gajjar, A., Raju, A.K., Gajjar, A., Menon, M., Shah, S.A.Y., Dani, S., Weinberg, A.: SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome. Biomedicines. 13, 1924 (2025). https://doi.org/10.3390/BIOMEDICINES13081924
20. Theodorakis, N., Nikolaou, M.: Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs. Biomedicines. 13, 135 (2025). https://doi.org/10.3390/BIOMEDICINES13010135
21. Sawami, K., Tanaka, A., Node, K.: Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives. Cardiovasc Diabetol. 23, 1–11 (2024). https://doi.org/10.1186/S12933-024-02500-Y/TABLES/4
22. Bae, J.H.: SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application. Diabetes Metab J. 49, 386–402 (2025). https://doi.org/10.4093/DMJ.2025.0220
23. Bongaerts, B., Kuss, O., Bonnet, F., Chen, H., Cooper, A., Fenici, P., Gomes, M.B., Hammar, N., Ji, L., Khunti, K., Medina, J., Nicolucci, A., Shestakova, M. V., Watada, H., Rathmann, W.: <scp>HbA1c</scp> trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global <scp>DISCOVER</scp> study. Diabetes Obes Metab. 25, 1890–1899 (2023). https://doi.org/10.1111/dom.15050
24. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.A. Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obesity Medicine, 2025; 100622. https://doi.org/10.1016/j.obmed.2025.100622
25. Alum, E.U. Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov Public Health* **22**, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
26. Shokravi, A., Seth, J., Mancini, G.B.J.: Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis. Cardiovasc Diabetol. 24, 370 (2025). https://doi.org/10.1186/S12933-025-02900-8

CITE AS: Muhindo Edgar (2026). GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes Management: Biochemical Mechanisms, Clinical Efficacy, and Translational Implications. IAA Journal of Biological Sciences 14(1):55-59. https://doi.org/10.59298/IAAJB/2026/1415559